Core Points - Cibus, Inc. announced leadership changes as part of its succession planning strategy, with Rory Riggs resigning as CEO and Peter Beetham appointed as Interim CEO [1][2] - The Board of Directors will search for a permanent CEO, considering both internal and external candidates [2] - Rory Riggs will remain as Chairman of the Board and expressed confidence in the leadership team during the transition [3] Company Overview - Cibus is a leading agricultural technology company focused on developing and licensing plant traits to seed companies for royalties, addressing productivity and sustainability challenges in agriculture [4] - The company utilizes its proprietary Rapid Trait Development System™ (RTDS®) for gene editing, aiming to develop traits more efficiently than conventional breeding methods [4] - Cibus has a pipeline of five productivity traits, including weed management in rice and disease resistance, which are its near-term focus [4]

SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today issued a correction relating to the rice conversion rates previously disclosed in its January 16, 2025 press release. The Company has concluded that the gene editing conversion rates of 10-25% in Rice have not been reconfirmed based upon subsequent experiments and high variability in the co ...

EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simo ...

SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Rory Riggs, Co-Founder, Chief Executive Officer, and Chairman, and Peter Beetham, Co-Founder, President, and Chief Operating Officer, will host a presentation at the Sidoti Micro Cap Conference. Presentation detailsDate: Thursday, Januar ...

Core Viewpoint - Cibus, Inc. has announced a securities purchase agreement to sell 9,040,000 shares of Class A Common Stock at a price of $2.50 per share, aiming to raise approximately $22.6 million for further development of its agricultural biotechnology pipeline and general corporate purposes [1][2]. Group 1: Offering Details - The offering includes pre-funded warrants and warrants to purchase an aggregate of 9,040,000 shares of Class A Common Stock, with the warrants exercisable upon stockholder approval at a price of $2.50 per share [1]. - The gross proceeds from the offering are expected to be around $22.6 million before deducting fees and expenses, with the offering anticipated to close on or about January 24, 2025 [2]. - A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering [3]. Group 2: Investor Warrants - Certain investors in the offering hold outstanding warrants to purchase up to 1,198,040 shares of Class A Common Stock, with the exercise price being reduced from $10.00 to $2.50 per share [4]. - The threshold for the redemption provision of the Investor Warrants has been lowered to $5.00 per share, and the termination date has been extended to five years following the closing of the offering [4]. Group 3: Company Overview - Cibus is a leader in gene editing technology focused on developing productivity traits for major global row crops, addressing challenges such as diseases and pests that cost the global economy approximately $300 billion annually [7]. - The company is not a seed company but a technology company that licenses traits to seed companies in exchange for royalties on seed sales [7]. - Cibus has developed a pipeline of five productivity traits, with some traits already in commercial development with leading seed companies [8].

SAN DIEGO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced it has entered into securities purchase agreements with existing investors of the Company, including institutional and strategic investors, as well as with the Company’s CEO, Rory Riggs, for the purchase and sale of 9,040,000 share ...

Culmination of Advances in Gene Editing Efficiency and Process Improvements Drives Standardization of Cibus' Gene Editing System Delivering Traits in a Customer's Elite Germplasm in less than 12 Months Cibus Announces Editing Milestone in the Continuing Development of its Soybean Platform SAN DIEGO, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced tha ...

Culmination of Advances in Gene Editing Efficiency and Process Improvements Drives Standardization of Cibus’ Gene Editing System Delivering Traits in a Customer’s Elite Germplasm in less than 12 Months Cibus Announces Editing Milestone in the Continuing Development of its Soybean Platform SAN DIEGO, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced th ...

Cibus' Rice Herbicide Tolerance (HT-3) Commercialization Efforts Continue Promising Progress to deliver a new Weed Management Solution for Farmers in the U.S. Cibus and its partners Albaugh and RTDC Continue Their Research and Development Collaboration to Enable Commercialization of Cibus' Clethodim-Tolerant HT-3 Rice Trait SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties ...

Cibus’ Rice Herbicide Tolerance (HT-3) Commercialization Efforts Continue Promising Progress to deliver a new Weed Management Solution for Farmers in the U.S. Cibus and its partners Albaugh and RTDC Continue Their Research and Development Collaboration to Enable Commercialization of Cibus’ Clethodim-Tolerant HT-3 Rice Trait SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royaltie ...